Immunotherapy before chemoradiation may boost esophageal cancer survival
NCT ID NCT07306663
First seen Jan 08, 2026 · Last updated May 22, 2026 · Updated 25 times
Summary
This phase 3 trial tests whether adding immunotherapy (sintilimab) plus chemotherapy before standard chemoradiotherapy helps people with inoperable esophageal cancer live longer. About 242 adults aged 18-75 with stage II-IVA esophageal squamous cell carcinoma will either receive two cycles of immunotherapy plus chemo followed by chemoradiotherapy, or chemoradiotherapy alone. The study measures overall survival, side effects, and cancer recurrence.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Jiangsu Cancer Hospital
Nanjing, Jiangsu, 210009, China
Conditions
Explore the condition pages connected to this study.